Geneoscopy

10/08/2026

This week, Dr. Erica Barnell spoke at the NCQA Health Innovation Summit: “Spotlight presentations: Innovation in Colorectal Cancer Screening" and "Quality Conversation: Closing the CRC Screening Gap: How We're Leaving 54 Million Patients Behind." We are sincerely appreciative of the opportunity to contribute to such impactful conversations. Raising awareness and sharing our findings about colorectal cancer is vital, and we are grateful for platforms that enable us to make a difference.

09/16/2026

At Geneoscopy, we're advancing gastrointestinal diagnostics with one goal in mind: helping more people access colorectal cancer screening.
ColoSense® combines FDA-approved RNA-based technology with an at-home collection experience. Recent nationwide availability through Labcorp expands access even further, helping more providers and patients incorporate colon cancer screening into routine care.
Every innovation begins with a simple belief:
Earlier detection leads to better outcomes.
We're proud to be helping shape the future of colorectal cancer screening.

09/03/2026

Last week, our co-founder, Dr. Erica Barnell, along with our Vice President of Market Access, Jackie Moriarty, and our Director of Market Access, Queentela Benjamin Abajuo Abajou, participated in the NextGeneration DX Summit in Washington, D.C. The conference brought together leading professionals and innovators from the diagnostics industry. During the event, Erica and Jackie spoke and led panels that reflected our company's mission to advance diagnostics and improve patient care. We are looking forward to next year's summit and are so glad we were able to share our story.

08/21/2026

When it comes to colorectal cancer, timing matters.
Colorectal cancer is one of the most preventable cancers when it's found early. That's why screening isn't simply about detecting cancer; it's also about identifying precancerous polyps before they become cancer.

At Geneoscopy, we believe innovation should remove barriers. ColoSense® was developed to make at-home screening easy while delivering advanced RNA-based technology that helps healthcare providers identify patients who may need follow-up care.
Because the best screening test is the one that gets completed.

08/13/2026

Colorectal cancer isn't just affecting older adults anymore.
For decades, colorectal cancer was considered a disease of aging. Today, we're seeing a different reality: rates are increasing in adults under 50, making awareness and timely screening more important than ever. Screening for average-risk adults now begins at age 45. At Geneoscopy, we're committed to advancing innovative screening solutions that meet patients where they are. Through RNA-based technology and our partnership with Labcorp, ColoSense® helps expand access to noninvasive colorectal cancer screening for today's screening population.
The future of colorectal cancer screening starts with early action, and that means getting screened.

08/11/2026

Getting screened for colorectal cancer doesn't have to be complicated. With ColoSense®, it's as easy as:
📦 Plan – Receive your kit at home and choose a time that works for you.
💩Poop – Collect your sample using our collection kit—no scraping your stool required.
📬 Pack – Secure your sample and send it back using the prepaid return packaging.
No bowel prep. No office visit. Just a simple, convenient screening experience from the comfort of your home.
At Geneoscopy, we're committed to making colorectal cancer screening easier so more people can get screened when it matters most.

08/06/2026

Colorectal cancer is rising in adults under 50, making awareness and early detection more important than ever. Because colorectal cancer often develops without symptoms, regular screening beginning at age 45 is one of the most powerful steps you can take to protect your health.

At Geneoscopy, our mission is to make screening more accessible, more convenient, and easier to complete. ColoSense® is our at-home colorectal cancer screening test designed to help more people get screened—without disrupting their daily lives.

Detection can save lives. Talk to your healthcare provider about whether ColoSense is right for you, and don't wait for symptoms to take action.

08/04/2026

Your health is worth the investment.
August is National Wellness Month, the perfect reminder to prioritize the habits that help you feel your best, including staying up to date on preventive health screenings.
Colorectal cancer is on the rise, especially in adults under 50, and it often develops without symptoms. That's why regular screening starting at age 45 is so important. Screening helps detect changes early when treatment can be more effective.

At Geneoscopy, our mission is to help more people get screened through innovative, patient-centered solutions. ColoSense® is an FDA-approved, noninvasive, at-home stool-based RNA screening test designed to make colorectal cancer screening simple, convenient, and more accessible.

This month, take one step toward a healthier future:
🩺Schedule your annual checkup.
🧑‍⚕️Talk to your healthcare provider about colorectal cancer screening.
👍Encourage someone you love to do the same.

Because wellness isn't just about how you feel today; it's about protecting your health for years to come.

07/31/2026

Listen to the TD Cowen Insights podcast, where our CEO, Andrew Barnell, discusses RNA-based diagnostics, CRC screenings, and much more with TD Cowen Life Science & Diagnostic Tools analyst Daniel Brennan, CFA.

Listen on Apple Music, Spotify, or wherever you get your podcasts.

Recorded on 07/09/26 TD Cowen Life Science & Diagnostic Tools analyst Dan Brennan speaks with Geneoscopy CEO Andrew Barnell post TD Cowen's 5th Annual Tools/Dx Revolution Conference to discuss GI healthcare and the future of GI cancer diagnostics, and Geneoscopy's innovations, partnerships, and grow...

07/28/2026

What a great article highlighting Geneoscopy's mission and the dedicated efforts of Erica Barnell, which have been instrumental to our growth.

Thank you, Steven Ruddy, for effectively showcasing our biotech origin story.

Read the article and learn more about how Geneoscopy and ColoSense came to be through Dr. Barnell's encounter with a colon cancer patient she met in residency.

Welcome to Biotech Leadership Conversations, a series of story-driven features spotlighting executives shaping innovation in biotech. Each piece reflects on a leader's journey and shares perspectives on leadership, strategy, and decision-making at critical inflection points.